Celsion Provides Summary of Research and Development Day Held on October 12, 2017
18 oct. 2017 08h30 HE
|
Celsion Corporation
LAWRENCEVILLE, N.J., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today provided a summary of GEN-1 immunotherapy-related presentations...
Celsion Provides Summary of Research and Development Day Held on Thursday, October 12, 2017
17 oct. 2017 08h30 HE
|
Celsion Corporation
LAWRENCEVILLE, N.J., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology development company, today provided a summary of ThermoDox® related presentations made during...
Celsion Announces Publication of the HEAT Study Manuscript in the High Impact Journal, Clinical Cancer Research
16 oct. 2017 08h30 HE
|
Celsion Corporation
80+ Month Overall Survival (HR = 0.63, Pvalue = 0.02) Discussed in the 285 Patient Sub-group Treated with ThermoDox® plus Standardized Radiofrequency Ablation (sRFA) Ongoing Phase III OPTIMA Study to...
Celsion to Host Research and Development (R&D) Day on Thursday, October 12, 2017
12 oct. 2017 11h02 HE
|
Celsion Corporation
LAWRENCEVILLE, N.J., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology development company, today announced that it will host a Research and Development (R&D) Day...
Celsion Corporation Announces Gross Proceeds of $15.6 Million from the Exercise of Existing Common Stock Warrants
04 oct. 2017 13h45 HE
|
Celsion Corporation
Financing Accomplished with Minimal New Equity Issuance Operating Runway Extended through 2018 LAWRENCEVILLE, N.J., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (the “Company”)...
Celsion to Host Research and Development Update October 12, 2017
04 oct. 2017 09h00 HE
|
Celsion Corporation
LAWRENCEVILLE, N.J., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology development company, today announced that it will host a Research and Development (R&D) Day...
Celsion Announces Final Clinical and Translational Research Data from its OVATION Study at the AACR Special Conference on Ovarian Cancer
03 oct. 2017 09h00 HE
|
Celsion Corporation
100% Disease Control; 86% Objective Response Rate and 86% R0 & R1 Surgical Resection Rate in All Patients Treated in Four Dose-Escalating Cohorts Clear Evidence of Biological Activity Including...
Celsion Provides Update on ThermoDox® in the Phase III OPTIMA Study of Primary Liver Cancer
27 sept. 2017 09h00 HE
|
Celsion Corporation
OPTIMA Study Enrollment is Approaching 70% Independent Data Monitoring Committee Provided Unanimous Recommendation to Continue Study in August 2017 Investigators Meetings in Thailand and China...
Celsion Announces Presentation of OVATION Study Findings at the Upcoming AACR Special Conference
24 août 2017 09h30 HE
|
Celsion Corporation
LAWRENCEVILLE, N.J., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today provided an update on its OVATION Study, a Phase Ib dose...
Celsion Corporation Reports Second Quarter 2017 Financial Results and Provides Business Update
15 août 2017 08h00 HE
|
Celsion Corporation
LAWRENCEVILLE, N.J., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced financial results for the quarter and six month period...